Cargando…

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

OBJECTIVES: The burden of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic review was conducted to identify evidence on mutation frequency, prognostic impact, clinical, patient-reported, and economic ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burnett, Heather, Emich, Helena, Carroll, Chris, Stapleton, Naomi, Mahadevia, Parthiv, Li, Tracy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939356/ https://www.ncbi.nlm.nih.gov/pubmed/33684140 http://dx.doi.org/10.1371/journal.pone.0247620

Ejemplares similares

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
por: Viteri, Santiago, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
por: Pan, Binyang, et al.
Publicado: (2023)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
por: Pacini, Laura, et al.
Publicado: (2021)

EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Wang, Fenfang, et al.
Publicado: (2020)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Vyse, Simon, et al.
Publicado: (2019)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
por: Kobayashi, Ikei S., et al.
Publicado: (2021)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
por: Qin, YanRu, et al.
Publicado: (2020)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Morita, Chie, et al.
Publicado: (2021)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
por: Low, Jia Li, et al.
Publicado: (2023)

Human Papillomavirus Infection and EGFR Exon 20 Insertions in Sinonasal Inverted Papilloma and Squamous Cell Carcinoma
por: Hirakawa, Hitoshi, et al.
Publicado: (2023)

Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC
por: Horn, Marcia K., et al.
Publicado: (2021)

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
por: Wang, Mengzhao, et al.
Publicado: (2022)

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
por: Yudong, Su, et al.
Publicado: (2018)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
por: Watanabe, Naohiro, et al.
Publicado: (2022)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
por: Imran, Mohd, et al.
Publicado: (2021)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_poph2eru3c7ndf9ue65vgkcd5n